Bio-Life Labs Announces First Public Presentation of Data on Flagship Skin Cancer Product, Carcinoderm.

LOS ANGELES -- Data Presented at Annual Pacific Dermatologic Association Indicates Promise of New Single-Use Treatment with Approximate "88% Post-treatment Negative Biopsies"

Bio-Life Labs, Inc. (OTCBB:BLFE) today announced the presentation of data on the Company's first forthcoming product, Carcinoderm(TM), a topical treatment that destroys skin cancer cells in a one-time application without harming surrounding healthy tissue. The data was presented in an August 13 speech at the 56th Annual Meeting of the Pacific Dermatologic Association (PDA) in Newport Beach, California.

In her presentation regarding future topical treatment options for skin cancers, Karen F. Han, M.D., Ph.D., a certified clinical dermatologist at the Palo Alto Medical Foundation, communicated FDA-conforming research by Dr. David Karam, M.D., Ph.D., that described Carcinoderm as "acting only on tumor cells in a receptor-specific fashion" in "a single application causing primary necrosis within 90 minutes." In describing Dr. Karam's current "open-label trial on over 900 basal cell carcinoma, squamous cell carcinoma and malignant melanoma" patients, her speech relayed "88% post-treatment negative biopsies showing no active cancer cells in all categories."

"Should it prove as effective as early trials indicate, and if dermatologists can be convinced to use it, I think that Carcinoderm will dramatically change the way we approach skin cancer," said Dr. Han, who foresees its use as an alternative to surgery.

The American Cancer Society estimates that during 2004 approximately one million new cases of basal cell or squamous cell carcinoma and about 59,350 new cases of malignant melanoma, the deadliest type of skin cancer, will be diagnosed. The ACS further estimates that skin cancer will claim the lives of approximately 9,800 Americans, 7,900 as a result of melanoma. Since 1997 the incidence of new melanoma cases in the U.S. has increased at an average of more than 5% per year, one of the highest growth rates for any type of cancer. By 2000 there were over 510,000 living skin cancer patients in the U.S. who had been diagnosed with melanoma. Although death rates from basal cell and squamous cell carcinomas are low, the ACS indicates that these cancers can cause considerable damage and disfigurement if left untreated. Global skin cancer statistics are equally alarming. The World Health Organization indicates that, in 2000, the number of newly diagnosed cases of melanoma was 132,600, with 37,000 deaths reported.

About Bio-Life Labs

Bio-Life, Labs, Inc. (www.biolifelabs.com) is a research-driven biotechnology company focused on discovery, development, manufacturing, and commercialization of breakthrough treatments for cancer, diabetes mellitus, and hepatitis C. Its first product candidate, Carcinoderm(TM), is a topical treatment that is designed to destroy skin cancer cells in patients diagnosed with basal cell carcinoma, squamous cell carcinoma, and malignant melanoma in a one-time application without harming surrounding healthy tissue. Carcinoderm is currently being studied in what the Company believes are FDA-conforming clinical trials with patients who have biopsy-confirmed cases in all three categories of skin cancer.

Bio-Life Labs' corporate headquarters is in Los Angeles, California; its research and development facility is located in the El Paso, Texas area.

Bio-Life Labs, Inc. cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. The inclusion of these statements should not be regarded as a representation by Bio-Life Labs that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Bio-Life Labs' business including, without limitation, statements about: difficulties or delays in research, development, testing, obtaining regulatory approval, producing and marketing its technologies and products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization, or that could result in recalls or product liability claims; the scope and validity of patent protection for its products; its ability to meet product development objectives; competition from other pharmaceutical or biotechnology companies; its ability to obtain additional financing to support its operations; its ability to attract and retain experienced scientists and management; as well as other risks detailed in Bio-Life's Securities and Exchange Commission filings. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Bio-Life Labs undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.